Vivos Therapeutics (VVOS) Competitors $2.08 -0.06 (-2.80%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.10 +0.02 (+0.72%) As of 05/21/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VVOS vs. MLSS, INO, NTRB, ZYXI, VANI, OM, HYPR, SURG, CTSO, and ICCMShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Milestone Scientific (MLSS), Inovio Pharmaceuticals (INO), Nutriband (NTRB), Zynex (ZYXI), Vivani Medical (VANI), Outset Medical (OM), Hyperfine (HYPR), SurgePays (SURG), Cytosorbents (CTSO), and IceCure Medical (ICCM). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. Milestone Scientific Inovio Pharmaceuticals Nutriband Zynex Vivani Medical Outset Medical Hyperfine SurgePays Cytosorbents IceCure Medical Vivos Therapeutics (NASDAQ:VVOS) and Milestone Scientific (NYSE:MLSS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, community ranking, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation. Do institutionals and insiders hold more shares of VVOS or MLSS? 26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 5.8% of Milestone Scientific shares are held by institutional investors. 3.0% of Vivos Therapeutics shares are held by insiders. Comparatively, 24.8% of Milestone Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is VVOS or MLSS more profitable? Milestone Scientific has a net margin of -52.01% compared to Vivos Therapeutics' net margin of -86.19%. Milestone Scientific's return on equity of -60.26% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vivos Therapeutics-86.19% -335.04% -93.58% Milestone Scientific -52.01%-60.26%-40.23% Which has better earnings & valuation, VVOS or MLSS? Milestone Scientific has lower revenue, but higher earnings than Vivos Therapeutics. Milestone Scientific is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivos Therapeutics$15.03M0.82-$13.58M-$1.73-1.20Milestone Scientific$8.61M9.05-$6.93M-$0.07-14.18 Which has more volatility & risk, VVOS or MLSS? Vivos Therapeutics has a beta of 7.31, indicating that its stock price is 631% more volatile than the S&P 500. Comparatively, Milestone Scientific has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Does the media prefer VVOS or MLSS? In the previous week, Vivos Therapeutics had 4 more articles in the media than Milestone Scientific. MarketBeat recorded 8 mentions for Vivos Therapeutics and 4 mentions for Milestone Scientific. Milestone Scientific's average media sentiment score of 0.00 beat Vivos Therapeutics' score of -0.05 indicating that Milestone Scientific is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor VVOS or MLSS? Vivos Therapeutics received 15 more outperform votes than Milestone Scientific when rated by MarketBeat users. Likewise, 60.71% of users gave Vivos Therapeutics an outperform vote while only 2.17% of users gave Milestone Scientific an outperform vote. CompanyUnderperformOutperformVivos TherapeuticsOutperform Votes1760.71% Underperform Votes1139.29% Milestone ScientificOutperform Votes22.17%Underperform Votes9097.83% Do analysts rate VVOS or MLSS? Vivos Therapeutics currently has a consensus price target of $6.10, suggesting a potential upside of 193.27%. Milestone Scientific has a consensus price target of $1.25, suggesting a potential upside of 25.91%. Given Vivos Therapeutics' higher possible upside, research analysts clearly believe Vivos Therapeutics is more favorable than Milestone Scientific.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Milestone Scientific 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVivos Therapeutics beats Milestone Scientific on 9 of the 17 factors compared between the two stocks. Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.25M$4.47B$5.35B$8.38BDividend YieldN/A43.64%5.22%4.10%P/E Ratio-0.3729.4326.8419.71Price / Sales0.8267.72391.39116.98Price / CashN/A51.0838.2534.62Price / Book9.456.236.794.50Net Income-$13.58M$68.16M$3.23B$248.18M7 Day Performance-31.58%18.33%4.07%1.14%1 Month Performance-5.45%23.04%12.52%15.18%1 Year Performance-5.45%20.61%16.83%6.55% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics1.4085 of 5 stars$2.08-2.8%$6.10+193.3%-5.5%$12.25M$15.03M-0.37160Earnings ReportMLSSMilestone Scientific1.1407 of 5 stars$0.93-2.6%$1.25+35.1%+26.5%$72.52M$8.63M-13.2230INOInovio Pharmaceuticals3.6613 of 5 stars$1.94+7.8%$12.20+528.9%-82.0%$71.15M$217,756.00-0.49320NTRBNutriband2.1833 of 5 stars$5.83+1.9%$13.00+123.0%+9.2%$65.03M$2.14M-8.2110Positive NewsZYXIZynex3.0267 of 5 stars$2.15+3.9%$6.00+179.1%-78.5%$65.01M$172.40M14.33770Gap DownVANIVivani Medical3.1262 of 5 stars$1.03-1.0%$4.00+288.3%-36.7%$61.02MN/A-2.2920News CoverageAnalyst ForecastOMOutset Medical1.3617 of 5 stars$16.29+6.5%$24.67+51.4%-66.3%$58.56M$113.69M-6.57520Analyst ForecastGap DownHigh Trading VolumeHYPRHyperfine3.5015 of 5 stars$0.73-1.9%$1.33+82.2%-33.5%$56.82M$12.89M-1.28190Analyst RevisionGap UpSURGSurgePays2.8404 of 5 stars$2.70-3.6%$8.75+224.1%-22.4%$55.11M$60.88M-2.3940CTSOCytosorbents2.0506 of 5 stars$0.87-0.1%$4.67+436.3%-7.4%$54.48M$35.59M-2.42220News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionICCMIceCure Medical2.0808 of 5 stars$0.97-5.8%$2.50+157.7%-5.5%$53.84M$3.29M-3.3460News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies Milestone Scientific Competitors Inovio Pharmaceuticals Competitors Nutriband Competitors Zynex Competitors Vivani Medical Competitors Outset Medical Competitors Hyperfine Competitors SurgePays Competitors Cytosorbents Competitors IceCure Medical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VVOS) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VVOS Stock Free VVOS Stock Alerts